• Home
  • Search Results
  • Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives.

Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives.

Bioorganic & medicinal chemistry letters (2005-06-01)
Zsolt Székelyhidi, János Pató, Frigyes Wáczek, Péter Bánhegyi, Bálint Hegymegi-Barakonyi, Dániel Erös, György Mészáros, Ferenc Hollósy, Doris Hafenbradl, Sabine Obert, Bert Klebl, György Kéri, László Orfi
ABSTRACT

SR protein-specific kinase-1 (SRPK-1) has been identified as a validated target for hepatitis B virus (HBV). A series of novel tricyclic quinoxaline derivatives was designed and synthesised as potential kinase inhibitory antiviral agents and was found to be active and selective for SRPK-1 kinase. Most of these novel compounds have drug-like properties according to experimentally determined LogP and LogS values.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Colchicine, ≥95% (HPLC), powder
Sigma-Aldrich
Acetophenone, ReagentPlus®, 99%
Sigma-Aldrich
Theophylline, anhydrous, ≥99%, powder
Sigma-Aldrich
Indole, ≥99%
Sigma-Aldrich
Benzimidazole, 98%
Sigma-Aldrich
Valerophenone, 99%
Sigma-Aldrich
Colchicine, suitable for plant cell culture, BioReagent, ≥95% (HPLC)
Sigma-Aldrich
Acetophenone, ≥98%, FG
Sigma-Aldrich
Propiophenone, 99%
Supelco
Acetophenone, analytical standard
Sigma-Aldrich
Indole, ≥99%, FG
Sigma-Aldrich
Butyrophenone, ≥99%
Sigma-Aldrich
Acetophenone, puriss. p.a., ≥99.0% (GC)
Supelco
Indole, analytical standard
Sigma-Aldrich
1,3-Dimethyl-8-phenylxanthine, crystalline
Sigma-Aldrich
Propiophenone, ≥99%